Intervention not reported
Treatment time: time for a single nebulised treatment (min) · children and adults with cystic fibrosis
1 finding from 1 review
- no estimate extracted3 studies · 88 participantsVery low
Findings
What do systematic reviews say?
1,181 questions · 1,197 findings · 144 reviews
No studies found 196 · 16.4%GRADE not reported 213 · 17.8%Very low 274 · 22.9%Low 296 · 24.7%Moderate 171 · 14.3%High 47 · 3.9%
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD
Treatment time nebulisation time (min) · children aged 6 ‐ 18 with cystic fibrosis
1 finding from 1 review
- no estimate extracted1 study · 22 participantsVery low
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD
Treatment time (min) · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted1 study · 10 participantsVery low
Summary of findings ‐ nebulisers for delivering tobramycin: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)
Treatment time (min) · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted1 study · 18 participantsVery low
Summary of findings ‐ nebulisers for delivering colistin: conventional systems vs AAD
Treatment time (seconds) · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted1 study · 15 participantsVery low
Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)
Treatment time (minutes) · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Treatment time (minutes) · children and adults with cystic fibrosis
1 finding from 1 review
- no estimate extracted3 studies · 932 participantsVery low
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD
Treatment time · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT
Treatment time (minutes) · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted1 study · 85 participantsLow
Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT
Quality of life CFQ‐R scores (treatment burden domain and respiratory domain) · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted1 study · 85 participantsVery low
Intervention not reported
Treatment time · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD
Treatment time · adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT
Treatment time (min) · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted4 studies · 103 participantsLow
Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)
Treatment time (minutes) · adults with cystic fibrosis
1 finding from 1 review
- no estimate extracted1 study · 13 participantsVery low
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs nebuliser
Treatment time (min) · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted2 studies · 8 participantsVery low
Intervention not reported
Comparison (reference treatment) · adults and children with focal seizures
The review found no eligible studies for this question.
1 finding from 1 review
- Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
Comparison (reference treatment) · adults and children with focal seizures
The review found no eligible studies for this question.
1 finding from 1 review
- Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
Comparison (reference treatment) · adults and children with generalised seizures*
The review found no eligible studies for this question.
1 finding from 1 review
- Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Osmotic‐release oral system methylphenidate vs placebo
Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy
Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyRR 2.8 [1.14, 6.89]1 study · 33 participantsModerate
Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only
Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy
Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of individuals withdrawing from treatment compared with risperidone and previous ASM only (low certainty).
1 finding from 1 review
- Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes onlyRR 0.65 [0.12, 3.59]1 study · 61 participantsLow